IDH2 and acute myeloid leukemia: Optimal responses induced by IDH, LSD1, and Menin inhibitors may be significantly improved by strategic partnering with other therapies: ongoing and future clinical studies will clarify the impact of these association therapies, appropriately extended to AML patients at various disease stages.